NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$2.56

+0.07 (+2.81 %)

(As of 10/29/2020 12:00 AM ET)

Add

Compare

Today's Range

$2.40

Now: $2.56▼

$2.63

50-Day Range

$2.48

MA: $2.72▼

$3.16

52-Week Range

$2.32

Now: $2.56▼

$6.05

Volume97,404 shs

Average Volume130,818 shs

Market Capitalization$60.23 million

P/E RatioN/A

Dividend YieldN/A

Beta1.58

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Oramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.25, Oramed Pharmaceuticals has a forecasted upside of 339.5% from its current price of $2.56.
Amount of Analyst Coverage
Oramed Pharmaceuticals has received no research coverage in the past 90 days.

3.1 Community Rank

Outperform Votes
Oramed Pharmaceuticals has received 296 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Oramed Pharmaceuticals has received 184 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Oramed Pharmaceuticals has received 61.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote “Outperform” if you believe ORMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Oramed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Oramed Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 16.10% of the stock of Oramed Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 3.99% of the stock of Oramed Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.57) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oramed Pharmaceuticals is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oramed Pharmaceuticals is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oramed Pharmaceuticals has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.32 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ORMP

Previous Symbol

CUSIPN/A

CIK1176309

Webwww.oramed.com

Phone844-967-2633

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio9.99

Quick Ratio9.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.70 million

Price / Sales22.31

Cash Flow$0.75 per share

Price / Cash Flow3.41

Book Value$1.12 per share

Price / Book2.29

Profitability

EPS (Most Recent Fiscal Year)$0.82

Net Income$-14,350,000.00

Net Margins-230.07%

Return on Equity-28.75%

Return on Assets-17.58%

Miscellaneous

Outstanding Shares23,527,000

Market Cap$60.23 million

Next Earnings Date11/25/2020 (Estimated)

OptionableOptionable

$2.56

+0.07 (+2.81 %)

(As of 10/29/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

How has Oramed Pharmaceuticals' stock been impacted by Coronavirus?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ORMP stock has decreased by 22.7% and is now trading at $2.56.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oramed Pharmaceuticals.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Oramed Pharmaceuticals.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) released its quarterly earnings data on Tuesday, July, 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.07. The biotechnology company earned $0.68 million during the quarter, compared to analyst estimates of $0.69 million. Oramed Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 28.75%.
View Oramed Pharmaceuticals' earnings history.

What price target have analysts set for ORMP?

2 analysts have issued 12-month target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $5.50 to $17.00. On average, they expect Oramed Pharmaceuticals' share price to reach $11.25 in the next twelve months. This suggests a possible upside of 339.5% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Some companies that are related to Oramed Pharmaceuticals include Urovant Sciences (UROV), Arbutus Biopharma (ABUS), OrganiGram (OGI), Aduro BioTech (ADRO), CTI BioPharma (CTIC), scPharmaceuticals (SCPH), Xeris Pharmaceuticals (XERS), Metacrine (MTCR), SUMMIT THERAPEU/S (SMMT), Paratek Pharmaceuticals (PRTK), Chiasma (CHMA), Tricida (TCDA), Galera Therapeutics (GRTX), Cassava Sciences (SAVA) and IMV (IMV).
View all competitors.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), Opko Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:

Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $2.56.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $60.23 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings